Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Jacquelin, Jolette"'
Autor:
James T. Raymond, Sherri Dudal, Jacquelin Jolette, Annick Cauvin, Petrina Rogerson, Anthony Peter Hall
Publikováno v:
Toxicologic pathology. 49(2)
Treatment of nonhuman primates and mice with a humanized antigen-binding fragment (Fab) antibody (UCBFab) inhibiting transforming growth factor β via daily inhalation for up to 13 weeks resulted in low systemic exposure but high local exposure in th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbe1aec7ea2e4d1ca07960dfd406dbae
https://pubmed.ncbi.nlm.nih.gov/33167807
https://pubmed.ncbi.nlm.nih.gov/33167807
Autor:
Nacera Mellal, Rogely W. Boyce, Kathrin Locher, Steven K. Boyd, Melanie Felx, Jacquelin Jolette, Nancy Doyle, Michael S. Ominsky, Sabina Buntich, Aurore Varela, Susan Y. Smith, Ian Pyrah
Publikováno v:
Journal of Bone and Mineral Research. 32:788-801
Romosozumab (Romo), a humanized sclerostin antibody, is a bone-forming agent under development for treatment of osteoporosis. To examine the effects of Romo on bone quality, mature cynomolgus monkeys (cynos) were treated 4 months post- ovariectomy (O
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed44c66ab6f4c9d2f32446e374384b22
https://doi.org/10.1002/jbmr.3036
https://doi.org/10.1002/jbmr.3036
Autor:
Aurora Varela, Luc Chouinard, Sabina Buntich, Nacera Mellal, Michael S. Ominsky, Peter C. Mann, Jacquelin Jolette, Rana Samadfam, Melanie Felx, Rogely W. Boyce, Kathrin Locher, Susan Y. Smith, Ian Pyrah
Publikováno v:
Regulatory Toxicology and Pharmacology. 81:212-222
Romosozumab is a humanized immunoglobulin G2 monoclonal antibody that binds and blocks the action of sclerostin, a protein secreted by the osteocyte and an extracellular inhibitor of canonical Wnt signaling. Blockade of sclerostin binding to low-dens
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a25664d91333c74a028c0e83da8c1e05
https://doi.org/10.1016/j.yrtph.2016.08.010
https://doi.org/10.1016/j.yrtph.2016.08.010
Autor:
Jacquelin Jolette, Lei Zhou, Rana Samadfam, Paul J. Kostenuik, Michael S. Ominsky, Susan Y. Smith
Publikováno v:
Journal of Bone and Mineral Research. 30:657-669
Postmenopausal osteoporosis is a chronic disease wherein increased bone remodeling reduces bone mass and bone strength. Antiresorptive agents including bisphosphonates are commonly used to mitigate bone loss and fracture risk. Osteoclast inhibition v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e6feb230ee975dcdd5f5305e5da638cf
https://doi.org/10.1002/jbmr.2401
https://doi.org/10.1002/jbmr.2401
Publikováno v:
Molecular and Integrative Toxicology ISBN: 9783319561905
Qualitative histopathology remains the gold standard for hazard identification and safety assessment of potential new therapeutics. Although, in most cases, qualitative histopathology has sufficient sensitivity to detect test article-related effects
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c116ce4267bacee3ae026434d0842d10
https://doi.org/10.1007/978-3-319-56192-9_8
https://doi.org/10.1007/978-3-319-56192-9_8
Publikováno v:
Journal of Bone and Mineral Metabolism. 33:161-172
Bazedoxifene (BZA) is a novel selective estrogen receptor modulator in clinical development for the prevention and treatment of postmenopausal osteoporosis. This preclinical study evaluated the efficacy and safety of BZA in preventing ovariectomy (OV
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9c9fd916185ce98f5794d6735ca7002
https://doi.org/10.1007/s00774-014-0580-z
https://doi.org/10.1007/s00774-014-0580-z
Autor:
Lorraine A. Fitzpatrick, Sanjay Kumar, Jacquelin Jolette, Peter Mansell, Susan Y. Smith, Robert E. Guldberg, Rana Samadfam, Sandra J. Hoffman
Publikováno v:
Journal of Bone and Mineral Research. 28:1653-1665
Rosiglitazone (RSG) is an antidiabetic drug that has been associated with increased peripheral fractures, primarily in postmenopausal women. In this report, we investigated the underlying mechanisms of RSG-associated bone loss in ovariectomized (OVX)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ebe0b1ec0acf04a0405ead8f0ffba669
https://doi.org/10.1002/jbmr.1918
https://doi.org/10.1002/jbmr.1918
Autor:
Ching He, Nancy Doyle, Erin Stevens, Padma K. Narayanan, Remi Jawando, Cen Xu, Nianyu Li, Madeline M. Fort, Kevin Salyers, Florence Poitout-Belissent, Riki Stevenson, Mai Phuong Nguyen, Katherine Sprugel, Vibha Jawa, Nancy E. Everds, Keith Bailey, Sam M Tran, Jacquelin Jolette
Publikováno v:
Toxicologic Pathology. 41:951-969
Cynomolgus monkeys dosed with a therapeutic monoclonal antibody (mAbY.1) at ≥50 mg/kg had unexpected acute thrombocytopenia (nadir ∼3,000 platelets/µl), sometimes with decreases in red cell mass. Increased activated macrophages, mitotic figures,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::705a5085d5ece89e6d49152525d560d7
https://doi.org/10.1177/0192623312474727
https://doi.org/10.1177/0192623312474727
Autor:
Gerald G. Long, Bassem Attalla, Sabile Trimm, Jacquelin Jolette, Susan Y. Smith, Nacera Mellal, Aurore Varela, Gary Hattersley, Michael S. Ominsky
Publikováno v:
Regulatory toxicology and pharmacology : RTP. 86
Prolonged treatment with human parathyroid hormone (hPTH) in rats results in development of bone tumors, though this finding has not been supported by clinical experience. The PTH type 1 receptor agonist abaloparatide, selected for its bone anabolic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0630eac7a934c44881189c150aa29a0c
https://pubmed.ncbi.nlm.nih.gov/28389324
https://pubmed.ncbi.nlm.nih.gov/28389324
Autor:
Michael S, Ominsky, Steven K, Boyd, Aurore, Varela, Jacquelin, Jolette, Melanie, Felx, Nancy, Doyle, Nacera, Mellal, Susan Y, Smith, Kathrin, Locher, Sabina, Buntich, Ian, Pyrah, Rogely W, Boyce
Publikováno v:
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 32(4)
Romosozumab (Romo), a humanized sclerostin antibody, is a bone-forming agent under development for treatment of osteoporosis. To examine the effects of Romo on bone quality, mature cynomolgus monkeys (cynos) were treated 4 months post- ovariectomy (O
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5c8d8f8530327ecd9957bc2f19dedd21
https://pubmed.ncbi.nlm.nih.gov/27865001
https://pubmed.ncbi.nlm.nih.gov/27865001